Compare Citius Pharmaceuticals Inc (CTXR) vs Enovix Corporation (ENVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Enovix Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Enovix Corporation trades at $2.43 (market cap $549.72M). The key difference: Enovix Corporation is far larger — about 40.4× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 6,635,687). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Enovix Corporation for 11 Days on average.
| CTXR | ENVX | |
|---|---|---|
Market Cap | $13.62M | $549.72M |
Volume | 132,438 | 6,635,687 |
Sector | Health | Industrials |
52-Week High | $1.82 | $13.19 |
52-Week Low | $0.48 | $2.50 |
Typical Hold Time | 16 Days | 11 Days |
Enterprise Value | $3.79M | $611.42M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
ENVX trades at $2.46, down 3.53% on the day, reflecting a bearish technical trend. The company is in a high-growth investment phase, with revenue growing to $36 million in 2026 but reporting significant losses. Recent news highlights a CEO transition and progress in battery manufacturing for defense and consumer electronics, while analyst consensus remains largely positive with a $10.75 price target.
The outlook is bifurcated: strong analyst buy ratings and institutional interest signal long-term potential, but high cash burn, persistent losses, and bearish technical indicators present substantial near-term risks. Investment hinges on successful commercialization and achieving profitability from current expansion efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →
